Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HWK-007 in Advanced Solid Tumors
NCT07444814Phase 1Recruiting
- Sponsor
- Whitehawk Therapeutics, Inc.
- Start
- Dec 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of HWK-007 in endometrial cancer (EC), ovarian cancer and non-small cell lung cancer (NSCLC) (5 arms), sponsored by Whitehawk Therapeutics, Inc. Primary endpoints: Maximum Tolerated Dose at 21 days, Maximum Administered Dose at 21 days and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
HWK-007
03
Conditions
endometrial cancer (EC)ovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07444814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444814.